These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2091058)

  • 1. Staging and target volume. Clinical problems in combined curietherapy and external radiotherapy.
    Volterrani F
    Rays; 1990; 15(4):476-80. PubMed ID: 2091058
    [No Abstract]   [Full Text] [Related]  

  • 2. Criteria for comparison of combined external radiotherapy and curietherapy.
    Sannazzari GL
    Rays; 1990; 15(4):539-45. PubMed ID: 2091065
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined external beam and interstitial radiotherapy. Radiobiological and clinical considerations.
    Biagini C
    Rays; 1990; 15(4):451-66. PubMed ID: 2091056
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment volumes and dose specification in radiotherapy.
    Cellini N; Arcovito G; Piermattei A; Valentini V
    Rays; 1990; 15(4):467-75. PubMed ID: 2091057
    [No Abstract]   [Full Text] [Related]  

  • 5. Volume correction factor in time dose relationships in brachytherapy.
    Supe SJ; Sasane JB; Gupta MK
    Strahlenther Onkol; 1987 May; 163(5):309-13. PubMed ID: 3589957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
    Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
    Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiobiological considerations of brachytherapy.
    Glicksman AS; Leith JT
    Oncology (Williston Park); 1988 Jan; 2(1):25-32. PubMed ID: 3079317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovations and advances in brachytherapy.
    Stitt JA; Thomadsen BR
    Semin Oncol; 1997 Dec; 24(6):696-706. PubMed ID: 9422265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is "pulse dose rate" curietherapy comparable to low dose rate brachytherapy?].
    Lartigau E
    Bull Cancer Radiother; 1995; 82(3):336-9. PubMed ID: 8554885
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical efficacy of brachytherapy combined with external-beam radiotherapy and repeated arterial infusion chemotherapy in patients with unresectable extrahepatic bile duct cancer.
    Nomura M; Yamakado K; Nomoto Y; Nakatsuka A; Ii N; Shoji K; Takeda K
    Int J Oncol; 2002 Feb; 20(2):325-31. PubMed ID: 11788896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined curietherapy and teletherapy: radiobiology of time-dose relationship.
    Magno L
    Rays; 1990; 15(4):507-15. PubMed ID: 2091062
    [No Abstract]   [Full Text] [Related]  

  • 12. The basic criteria of the Paris system.
    Loasses A
    Rays; 1990; 15(4):489-99. PubMed ID: 2091060
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer.
    Kirisits C; Pötter R; Lang S; Dimopoulos J; Wachter-Gerstner N; Georg D
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):901-11. PubMed ID: 15936576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy for the treatment of primary vaginal cancer.
    Samant R; Tam T; Dahrouge S; E C
    Radiother Oncol; 2005 Nov; 77(2):133-6. PubMed ID: 16260055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Manchester system. Validity and principles.
    Bianchini G
    Rays; 1990; 15(4):481-8. PubMed ID: 2091059
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
    Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
    Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimum placement of radiation sources in the planning of interstitial radiotherapy].
    Zamiatin OA; Sushchikhina MA; Klepper LA
    Med Radiol (Mosk); 1986 Oct; 31(10):23-8. PubMed ID: 3773657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
    Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.
    Singh AM; Gagnon G; Collins B; Niroomand-Rad A; McRae D; Zhang Y; Regan J; Lynch J; Dritschilo A
    Prostate; 2005 Jan; 62(1):54-60. PubMed ID: 15389809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.